As Of June 30, 2024, Phathom Pharmaceuticals' Cash And Cash Equivalents Were $276.2M, The Company Believes It Will Have Sufficient Capital To Fund Operations Through The End Of 2026
As Of June 30, 2024, Phathom Pharmaceuticals' Cash And Cash Equivalents Were $276.2M, The Company Believes It Will Have Sufficient Capital To Fund Operations Through The End Of 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.